retatrutide weight loss results clinical trial Retatrutide: A Multi-Receptor Approach to Management Eli Lilly infiltrates anti-obesity market

Semaglutide targets one receptor (GLP-1)

Update: An October 2024 Clinical Practice Guidance joint statement by multiple medical societies (American Society of Anesthesiologists (ASA), American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons) states that most patients should continue taking their GLP-1 drugs before elective surgery

The primary goal is not weight loss, it is receptor adaptation

This tag-team approach also means patients may experience more substantial weight loss results compared to medications that only target GLP-1 receptors

For a first-time injector, that last part matters more than it sounds